Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients

Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients

<i>Pexa-Vec</i> is an engineered Wyeth-strain vaccinia oncolytic virus (OV), which has been tested extensively in clinical trials, demonstrating enhanced cytotoxic T cell infiltration into tumours following treatment. Favourable immune consequences to <i>Pexa-Vec</i> include...

Full description

Bibliographic Details
Main Authors:	Emma J. West, Karen J. Scott, Emma Tidswell, Kaidre Bendjama, Nicolas Stojkowitz, Monika Lusky, Marta Kurzawa, Raj Prasad, Giles Toogood, Christy Ralph, D. Alan Anthoney, Alan A. Melcher, Fiona J. Collinson, Adel Samson
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Cancers
Subjects:	vaccinia virus oncolytic virus therapy immunotherapy biomarkers interferon response immune checkpoint blockade
Online Access:	https://www.mdpi.com/2072-6694/14/9/2181

Similar Items

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
by: Samantha Turnbull, et al.
Published: (2015-12-01)

Recent progress in combination therapy of oncolytic vaccinia virus
by: Seyedeh Nasim Mirbahari, et al.
Published: (2024-03-01)

Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
by: Mengyuan Li, et al.
Published: (2023-09-01)

Radiation-Induced Cellular Senescence Reduces Susceptibility of Glioblastoma Cells to Oncolytic Vaccinia Virus
by: Quinn T. Storozynsky, et al.
Published: (2023-06-01)

A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells
by: Yanrong Zhou, et al.
Published: (2023-01-01)

Oncolytic vaccinia virus and cancer immunotherapy
by: Lihua Xu, et al.
Published: (2024-01-01)

Tachypleus tridentatus Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth
by: Gongchu Li, et al.
Published: (2018-06-01)

High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
by: Tiphaine Delaunay, et al.
Published: (2020-09-01)

Development of the drug oncolytic immunotherapy based on vaccinia viruses <i>(Vaccinia virus, Orthopoxvirus, Chordopoxvirinae, Poxviridae)</i> against breast cancer
by: T. V. Bauer, et al.
Published: (2020-02-01)

Construction of three strains of recombinant oncolytic vaccinia virus and their anti-tumor activity
by: LI Dan-yang, FANG Jing-jing, TANG Hui
Published: (2020-04-01)

Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase
by: S. M. Bakhtiar Ul Islam, et al.
Published: (2020-01-01)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
by: Cao-Sang Truong, et al.
Published: (2022-02-01)

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
by: Dobrin D. Draganov, et al.
Published: (2019-03-01)

Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)
by: Shuguang Zuo, et al.
Published: (2021-02-01)

Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma
by: Lili Deng, et al.
Published: (2022-03-01)

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
by: Franck Gallardo, et al.
Published: (2020-11-01)

Oncolytic Vaccinia Virus Expressing <i>Aphrocallistes vastus</i> Lectin as a Cancer Therapeutic Agent
by: Tao Wu, et al.
Published: (2019-06-01)

Haliotis discus discus Sialic Acid-Binding Lectin Reduces the Oncolytic Vaccinia Virus Induced Toxicity in a Glioblastoma Mouse Model
by: Gongchu Li, et al.
Published: (2018-04-01)

Effects of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins on Hepatocellular Carcinoma Cells
by: Yanrong Zhou, et al.
Published: (2023-02-01)

Collateral Lethal Effects of Complementary Oncolytic Viruses
by: Justin W. Maroun, et al.
Published: (2020-09-01)

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus
by: Claudia Hill, et al.
Published: (2021-06-01)

Oncolytic Virotherapy for Cancer: Clinical Experience
by: Shyambabu Chaurasiya, et al.
Published: (2021-04-01)

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
by: M. Moehler, et al.
Published: (2019-08-01)

Vaccinia virus-based vector against infectious diseases and tumors
by: Ziling Zhang, et al.
Published: (2021-06-01)

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
by: Boris R. Minev, et al.
Published: (2019-08-01)

Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
by: Jérémy Béguin, et al.
Published: (2020-08-01)

pH Sensitive Erythrocyte-Derived Membrane for Acute Systemic Retention and Increased Infectivity of Coated Oncolytic Vaccinia Virus
by: Kaelan T. Samoranos, et al.
Published: (2022-08-01)

Oncolytic vaccinia virus induces a novel phenotype of CD8+ effector T cells characterized by high ICOS expression
by: Midori Yamashita, et al.
Published: (2021-03-01)

Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus
by: Zong Sheng Guo, et al.
Published: (2017-12-01)

Design and Engineering of Deimmunized Vaccinia Viral Vectors
by: Kevin Song, et al.
Published: (2020-11-01)

Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy
by: Xinjun Liu, et al.
Published: (2022-09-01)

Oncolytic Vaccinia Virus Expressing White-Spotted Charr Lectin Regulates Antiviral Response in Tumor Cells and Inhibits Tumor Growth In Vitro and In Vivo
by: Xue Wang, et al.
Published: (2021-05-01)

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles
by: Yaohe Wang, et al.
Published: (2010-01-01)

Vaccinia Virus in Household Environment during Bovine Vaccinia Outbreak, Brazil
by: Felipe L. Assis, et al.
Published: (2013-12-01)

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
by: Jérémy Béguin, et al.
Published: (2020-12-01)

Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma
by: Wei Wei, et al.
Published: (2024-12-01)

Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer
by: Seoyul Lee, et al.
Published: (2022-06-01)

A model of the artificial metastasis of human epidermoid carcinoma A431 in nude mice for examination of the oncolytic activity of vaccinia virus
by: G. V. Kochneva, et al.
Published: (2015-12-01)

Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery
by: Dana Haddad
Published: (2017-05-01)

Oncolytic Vaccinia Virus Harboring <i>Aphrocallistes vastus</i> Lectin Inhibits the Growth of Hepatocellular Carcinoma Cells
by: Riqing Jiang, et al.
Published: (2022-06-01)